Rep. Julie Johnson Sells Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Stock

Posted by Stuart Ham on May 18th, 2025

Representative Julie Johnson (D-Texas) recently sold shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN). In a filing disclosed on May 14th, the Representative disclosed that they had sold between $1,001 and $15,000 in Regeneron Pharmaceuticals stock on April 1st. The trade occurred in the Representative’s “MERRILL LYNCH TAX EFFICIENT CORE” account.

Representative Julie Johnson also recently made the following trade(s):

Purchased $1,001 – $15,000 in shares of Fidelity National Information Services (NYSE:FIS) on 4/30/2025.
Sold $1,001 – $15,000 in shares of Blackstone (NYSE:BX) on 4/22/2025.
Purchased $1,001 – $15,000 in shares of Fidelity National Information Services (NYSE:FIS) on 4/22/2025.
Sold $1,001 – $15,000 in shares of United Parcel Service (NYSE:UPS) on 4/15/2025.
Sold $1,001 – $15,000 in shares of United Parcel Service (NYSE:UPS) on 4/11/2025.
Purchased $1,001 – $15,000 in shares of 3M (NYSE:MMM) on 4/11/2025.
Sold $1,001 – $15,000 in shares of DT Midstream (NYSE:DTM) on 4/7/2025.
Sold $1,001 – $15,000 in shares of Intuitive Surgical (NASDAQ:ISRG) on 4/7/2025.
Sold $1,001 – $15,000 in shares of Howmet Aerospace (NYSE:HWM) on 4/7/2025.
Sold $1,001 – $15,000 in shares of Carlisle Companies (NYSE:CSL) on 4/7/2025.

Regeneron Pharmaceuticals Stock Performance

REGN traded up $9.33 on Friday, hitting $594.32. The company had a trading volume of 935,531 shares, compared to its average volume of 789,938. The stock has a market cap of $64.17 billion, a price-to-earnings ratio of 15.53, a price-to-earnings-growth ratio of 2.34 and a beta of 0.43. The company has a debt-to-equity ratio of 0.09, a current ratio of 4.73 and a quick ratio of 3.95. The company’s fifty day moving average price is $599.96 and its 200 day moving average price is $682.98. Regeneron Pharmaceuticals, Inc. has a 1-year low of $520.50 and a 1-year high of $1,211.20.

Regeneron Pharmaceuticals (NASDAQ:REGN – Get Free Report) last issued its quarterly earnings data on Tuesday, April 29th. The biopharmaceutical company reported $8.22 earnings per share for the quarter, missing analysts’ consensus estimates of $8.83 by ($0.61). Regeneron Pharmaceuticals had a return on equity of 16.32% and a net margin of 31.07%. The firm had revenue of $3.03 billion during the quarter, compared to analyst estimates of $3.40 billion. During the same quarter in the previous year, the firm posted $9.55 earnings per share. Regeneron Pharmaceuticals’s quarterly revenue was down 3.7% compared to the same quarter last year. Equities analysts predict that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, June 6th. Stockholders of record on Tuesday, May 20th will be issued a dividend of $0.88 per share. The ex-dividend date of this dividend is Tuesday, May 20th. This represents a $3.52 annualized dividend and a dividend yield of 0.59%. Regeneron Pharmaceuticals’s dividend payout ratio is 8.96%.

Institutional Trading of Regeneron Pharmaceuticals

A number of hedge funds and other institutional investors have recently made changes to their positions in REGN. Capital International Investors boosted its holdings in Regeneron Pharmaceuticals by 41.6% in the fourth quarter. Capital International Investors now owns 4,736,929 shares of the biopharmaceutical company’s stock valued at $3,373,859,000 after acquiring an additional 1,390,534 shares during the last quarter. Norges Bank bought a new position in Regeneron Pharmaceuticals in the fourth quarter valued at about $802,036,000. GAMMA Investing LLC boosted its holdings in Regeneron Pharmaceuticals by 89,825.0% in the first quarter. GAMMA Investing LLC now owns 815,620 shares of the biopharmaceutical company’s stock valued at $517,291,000 after acquiring an additional 814,713 shares during the last quarter. Price T Rowe Associates Inc. MD boosted its holdings in Regeneron Pharmaceuticals by 63.5% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 2,085,447 shares of the biopharmaceutical company’s stock valued at $1,485,527,000 after acquiring an additional 810,144 shares during the last quarter. Finally, Nuveen LLC bought a new position in Regeneron Pharmaceuticals in the first quarter valued at about $343,764,000. 83.31% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

REGN has been the subject of a number of analyst reports. Guggenheim reduced their price objective on shares of Regeneron Pharmaceuticals from $940.00 to $810.00 and set a “buy” rating for the company in a research note on Thursday, May 1st. Truist Financial cut their price target on Regeneron Pharmaceuticals from $975.00 to $940.00 and set a “buy” rating for the company in a report on Wednesday, April 30th. The Goldman Sachs Group cut their price target on Regeneron Pharmaceuticals from $917.00 to $804.00 and set a “buy” rating for the company in a report on Wednesday, April 30th. Leerink Partnrs upgraded Regeneron Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a report on Wednesday, February 5th. Finally, Bernstein Bank cut their price target on Regeneron Pharmaceuticals from $1,070.00 to $1,000.00 in a report on Tuesday, February 4th. One investment analyst has rated the stock with a sell rating, four have assigned a hold rating, nineteen have issued a buy rating and three have issued a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $890.60.

Read Our Latest Research Report on REGN

About Representative Johnson

Julie Johnson (Democratic Party) is a member of the U.S. House, representing Texas’ 32nd Congressional District. She assumed office on January 3, 2025. Her current term ends on January 3, 2027.

Johnson (Democratic Party) ran for election to the U.S. House to represent Texas’ 32nd Congressional District. She won in the general election on November 5, 2024.

Julie Johnson earned a B.A. in history and government from the University of Texas at Austin in 1987 and a J.D. from the University of Houston Law Center in 1991. Johnson’s career experience includes working as an attorney.

About Regeneron Pharmaceuticals

(Get Free Report)

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.